NEKTAR THERAPEUTICS (NKTR:NASDAQ)
$80.45 2.95 (3.8065%)
Analysed NEKTAR THERAPEUTICS (NKTR:NASDAQ) News Sources
Nektar Therapeutics (NKTR) Is Up 12.1% After REZPEG Data And Lawsuits Collide - Has The Bull Case Changed?
05-04-2026
yahoo.com
Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting
28-03-2026
yahoo.com
Apogee strengthens case for longer-lasting eczema drug
23-03-2026
biopharmadive.com
Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting
20-03-2026
yahoo.com
2 Healthcare Stocks to Buy Before They Get Bought Out
20-03-2026
fool.com
How The Nektar Therapeutics (NKTR) Story Is Shifting Around Rezpeg And Fair Value Estimates
20-03-2026
yahoo.com
DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls
17-03-2026
yahoo.com
Wall Street Analysts See a 77.28% Upside in Nektar (NKTR): Can the Stock Really Move This High?
16-03-2026
yahoo.com
Company News for Mar 16, 2026
16-03-2026
yahoo.com
Nektar Q4 Earnings & Revenues Trump Estimates, Pipeline in Focus
13-03-2026
yahoo.com
What is the current price of NEKTAR THERAPEUTICS (NKTR:NASDAQ)?
The current price of NEKTAR THERAPEUTICS (NKTR:NASDAQ) is $80.45.
NEKTAR THERAPEUTICS (NKTR:NASDAQ) absolute price change since previous trading day?
The absolute price change of NEKTAR THERAPEUTICS (NKTR:NASDAQ) since the previous trading day is $2.95.
NEKTAR THERAPEUTICS (NKTR:NASDAQ) percentage price change since previous trading day?
The percentage price change of NEKTAR THERAPEUTICS (NKTR:NASDAQ) since the previous trading day is 3.8065%.
What is the most recent average sentiment score for NEKTAR THERAPEUTICS (NKTR:NASDAQ)?
The most recent average sentiment score for NEKTAR THERAPEUTICS (NKTR:NASDAQ) is 76 out of 100.
What is the most recent average sentiment for NEKTAR THERAPEUTICS (NKTR:NASDAQ)?
The most recent sentiment for NEKTAR THERAPEUTICS (NKTR:NASDAQ) is .
SEC-8K** Filing Available For NEKTAR THERAPEUTICS (NKTR:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.